AC Immune Hosts Key Opinion Leader Event: ‘Untangling’ Tau Pathology to Treat Alzheimer’s and Neurodegenerative Diseases
AC Immune SA, a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced highlights from its Key Opinion Leader (KOL) meeting focused on “untangling” Tau pathology as an important therapeutic and diagnostic target for Alzheimer’s disease (AD) and other neurodegenerative diseases, held in New York City today at 12pm ET. The archived webcast of the event can be viewed here.